PepSee goes public — a new software tool for therapeutic peptide analysis & design

webinar

Thu, 25 Jan 2018, 16:00 CET (Berlin)

Dr. Marcus Gastreich, BioSolveIT GmbH, St. Augustin, Germany

PepSee goes public — a new software tool for therapeutic peptide analysis & design

In collaboration with Zealand Pharma, a leading and experienced therapeutic peptide specialist in Copenhagen, we conceived a tool with the major focus of having it rolled-out and operational ASAP, targeting the most relevant problems and most ugly time-eaters first thus boosting the efficiency of the organization. After approx. 2 years, we can now roll out the tool in its current status to the general public, and academics can use it for free.

PepSee sports, amongst others:

  • visual pattern recognition support for SAR work
  • versatile colorings, for ex. by mutation differences to a reference peptide
  • a plethora of sorting and filtering facilities
  • FASTA, PLN, and TXT import
  • XLS export
  • on-the-fly alignment including manual intervention
  • interfaces to predictive methods such as fibrillation highlighting, and allows validation and registration of new sequences
  • A first PDF text mining function pulling peptides from patents et al.

Current news

VAST Just Got Bigger — The September 2026 Update
September 17, 2026 09:00 CEST
More compounds. More chemistry. More opportunities to discover your next active. This August, explore Enamine’s largest compound catalog with infiniSee xREAL as BioSolveIT’s Tool of the Month. XtalPi has expanded its VAST Chemical Space, giving you access to almost six billion virtual product molecules built from over 25,000 carefully selected...
Read on
category
Events
Boston Event: Expanding Molecular Diversity with CORE
September 15, 2026 17:27 CEST
Chemical Space Exploration Meets AI in Boston BioSolveIT and Onepot.AI invite you to an evening of science, drinks, and conversation at D16, the speakeasy beneath Dillon’s in Boston. Join us on September 30, 2026, for two very concise presentations exploring how ultra-large Chemical Spaces and artificial intelligence can open new...
Read on
category
Events
Beyond the Flatland: sp³-Rich Fragments Unlock Novel Kinase Chemotypes: Free Webinar!
September 15, 2026 10:40 CEST
Kinases are among the most intensively pursued target families in drug discovery, yet the chemical matter screened against them remains surprisingly narrow. Conventional kinase-focused libraries are dominated by flat, heteroaromatic compounds, while saturated, three-dimensional molecules stay largely underexplored. That narrow structural diversity makes it harder to find genuinely novel chemotypes,...
Read on